FDA expedites review of Janssen-Medivir's hep C drug simeprevir

05/14/2013 | Star-Ledger (Newark, N.J.), The

The FDA granted priority-review status to Janssen Research & Development and Medivir's experimental drug simeprevir as a treatment for genotype 1 chronic hepatitis C. Janssen said the FDA is likely to make a final decision this year. Simeprevir, intended to be taken with pegylated interferon and ribavirin, inhibits the protease enzyme that allows the virus to reproduce itself inside cells.

View Full Article in:

Star-Ledger (Newark, N.J.), The

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Food & Drug Associate
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
Multiple Locations, SL_Multiple Locations